| PacBio CEO, CFO Plan Retirements and More People on the Move | Editors | 07/07/20 | National |
| Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs | Sarah de Crescenzo | 07/01/20 | San Francisco |
| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug | Frank Vinluan | 06/18/20 | Seattle |
| FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19 | Sarah de Crescenzo | 06/15/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation | Sarah de Crescenzo | 06/03/20 | Boston |
| Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech | Frank Vinluan | 06/02/20 | Seattle |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs | Sarah de Crescenzo | 05/28/20 | Seattle |
| AbCellera Raises $105M to Advance Antibody Discovery Operations | Sarah de Crescenzo | 05/27/20 | Seattle |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod | Frank Vinluan | 04/22/20 | New York |
| Synthorx’s Shawver Joins Silverback Therapeutics as New Top Exec | Sarah de Crescenzo | 04/22/20 | Seattle |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| New COVID-19 Special Reports Explore Clinical Research During the Pandemic | Editors | 04/21/20 | Boston |
| Seattle Genetics Gets Early FDA Nod for Breast Cancer Combo Drug | Sarah de Crescenzo | 04/18/20 | Seattle |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
